Encouraging results from the phase II GEOMETRY mono-1 trial led to the FDA approval of the MET-inhibiting oral agent capmatinib; patients with qPCR tissue-confirmed METex14 skipping NSCLC, that was retrospectively assessed by Foundation One® Liquid Cdx, achieved an ORR of 68% in first-line and 41% in second- or third-line treatment with capmatinib. This evidence concerns the gene MET and non-small cell lung carcinoma.